Erik W Bloomquist

6PUBLICATIONS
31CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Food properties (incl. characteristics and health benefits)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Mar 07, 2024
US Food and Drug Administration Approval Summary: Talazoparib in Combination With Enzalutamide for Treatment of Patients With Homologous Recombination Repair Gene-Mutated Metastatic Castration-Resistant Prostate Cancer.

Brian L Heiss, Elaine Chang, Xin Gao

|Mar 05, 2024
FDA Approval Summary: Enfortumab Vedotin plus Pembrolizumab for Cisplatin-Ineligible Locally Advanced or Metastatic Urothelial Carcinoma.

William F Maguire, Daniel Lee, Chana Weinstock

|Dec 21, 2023
FDA Approval Summary: Olaparib in Combination With Abiraterone for Treatment of Patients With BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer.

Jaleh Fallah, Jianjin Xu, Chana Weinstock

|Aug 18, 2023
FDA Approval Summary: Ribociclib Indicated for Male Patients with Hormone Receptor-Positive, HER2-Negative Advanced or Metastatic Breast Cancer.

Jennifer J Gao, Christy L Osgood, Zhou Feng

|Apr 27, 2023
US Food and Drug Administration Expanded Adjuvant Indication of Abemaciclib in High-Risk Early Breast Cancer.

Melanie Royce, Flora Mulkey, Christy Osgood

|Feb 13, 2023
US Food and Drug Administration Approval Summary: Fam-Trastuzumab Deruxtecan-nxki for Human Epidermal Growth Factor Receptor 2-Low Unresectable or Metastatic Breast Cancer.

Preeti Narayan, Asma Dilawari, Christy Osgood

Pageof 1

Frequent Collaborators

6 joint publications

Laleh Amiri-Kordestani

5 joint publications

Shenghui Tang

5 joint publications

Richard Pazdur

4 joint publications

William F Pierce